Medido.
- Conditions
- Parkinson's DiseaseTherapy adherenceMedicationZiekte van ParkinsonTherapietrouwMedicatie
- Registration Number
- NL-OMON22331
- Lead Sponsor
- Mw. L. ter Brake-Berning, nurse practitioner Parkinson en Mw L. Vree Egberts, researcher
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
The patient:
1. Is older than forty years;
Exclusion Criteria
Patients:
1. Not capable of completing the questionnaires;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary parameter of this study is the physical disability of Parkinson’s patients. To measure the physical disability, the AMC Linear Disability Score (ALDS) will be used. The ALDS checks the activities in daily life of the patient. The ALDS is a flexible, validated and clinimetrically sound and flexible instrument to assess the level of disability in patients with Parkinson’s disease.
- Secondary Outcome Measures
Name Time Method 1. Does the use of Medido improve the Quality of life of Parkinson’s patients compared with the current method of medication distribution to Parkinson’s patients after a follow-up period of 3 months, as measured by the PDQ39 questionnaire;<br /><br>2. What is the cost effectiveness ratio expressed in Cost per QALY of the Medido for Parkinson’s patients relative to current treatment for Parkinson’s patients, as measured by the Euroqol 5D (EQ5D);<br /><br>3. What is the Quality of life for personal care givers for Parkinson’s patients for care givers in the Medido group versus regular care group, as measured by the PDQ carer questionnaire;<br /><br>4. What is the patient experience of motor symptoms in the Medido group versus regular care group, as measured by the Visual Analog Scale (VAS);<br /><br>5. How many times do you have a off-period during the day, as measured by the MDS-UPDRS.